News
BY SYLVESTER OJENAGBON Chronic kidney disease is a significant public health concern in Nigeria. Studies show its ...
KYOTO—Researchers have safely transplanted nerve cells generated from induced pluripotent stem (iPS) cells into the brains of ...
Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...
Sep. 18, 2024 — A team developed a human iPS cell-derived kidney organoid ... that could be a significant step in the treatment of chronic kidney disease. The method can predict the progression ...
Raad B. Chowdhury, MD, and Shruti Gupta, MD, MPH, are onconephrologists in the Division of Nephrology at Brigham and Women's Hospital (BWH). They are first and senior authors, respectively, of a paper ...
Beaver County Times on MSN2d
Dr. Cynthia Maro: New tests, treatments for feline kidney disease improve quality of lifeEarly detection, through regular urine and blood tests, ensures cats remain comfortable and active for as long as possible. Understanding Feline Renal Disease. The kidneys’ role ...
Among 20 patients who got the kidney and cell transplants, 15 of them, including Wiederhoeft and Okey, were able to stop ...
A first in human proof of concept phase I clinical study of VAS-101 (Vasceptor®; topical curcumin gel) in sickle cell disease (SCD) is underway. The study is being conducted by the Foundation for ...
This is the first study to document the creation of a dedicated inpatient onconephrology service. The researchers highlight some of the challenges and future directions as well.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
While doctors determined he broke his right clavicle, they wanted to do a follow-up MRI to understand why. The reason felt ...
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results